Indeed, such tests guide clinical decisions in a similar fashion to trastuzumab administration on the basis of HER2 positivity or antiestrogen treatment on the basis of estrogen receptor positivity in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.